• Apimeds Pharmaceuticals US said it will file an emergency action in the Delaware Court of Chancery under 8 Del. C. § 225 challenging a written-consent effort that it says unlawfully replaced its board.
• The company said it will seek a declaration that the consent is void and request a temporary restraining order to prevent the purported new directors from taking corporate actions.
• Apimeds Pharmaceuticals US said the disputed consent relied on 6,416,365 shares that it says are subject to an irrevocable proxy granted under a December 1, 2025 stockholder support and lock-up agreement.
• Separately, the company said it engaged legal counsel in Seoul to pursue remedies under Korean law related to Inscobee’s conduct and governance obligations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-034786), on March 26, 2026, and is solely responsible for the information contained therein.